These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24041012)

  • 1. [18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models.
    Tegnebratt T; Lu L; Lee L; Meresse V; Tessier J; Ishii N; Harada N; Pisa P; Stone-Elander S
    EJNMMI Res; 2013 Sep; 3(1):67. PubMed ID: 24041012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches.
    Tegnebratt T; Ruge E; Bader S; Ishii N; Aida S; Yoshimura Y; Ooi CH; Lu L; Mitsios N; Meresse V; Mulder J; Pawlak M; Venturi M; Tessier J; Stone-Elander S
    EJNMMI Res; 2014 Dec; 4(1):34. PubMed ID: 26116108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.
    Wada M; Horinaka M; Yamazaki T; Katoh N; Sakai T
    PLoS One; 2014; 9(11):e113217. PubMed ID: 25422890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
    McKinley ET; Smith RA; Zhao P; Fu A; Saleh SA; Uddin MI; Washington MK; Coffey RJ; Manning HC
    J Nucl Med; 2013 Mar; 54(3):424-30. PubMed ID: 23341544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973.
    Baudy AR; Dogan T; Flores-Mercado JE; Hoeflich KP; Su F; van Bruggen N; Williams SP
    EJNMMI Res; 2012 May; 2(1):22. PubMed ID: 22651703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
    Geven EJ; Evers S; Nayak TK; Bergström M; Su F; Gerrits D; Franssen GM; Boerman OC
    Contrast Media Mol Imaging; 2015; 10(3):203-10. PubMed ID: 25204436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.
    Kraeber-Bodéré F; Carlier T; Naegelen VM; Shochat E; Lumbroso J; Trampal C; Nagarajah J; Chua S; Hugonnet F; Stokkel M; Gleeson F; Tessier J
    J Nucl Med; 2012 Dec; 53(12):1836-46. PubMed ID: 23143089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.
    Flores LG; Yeh HH; Soghomonyan S; Young D; Bankson J; Hu Q; Alauddin M; Huff V; Gelovani JG
    Mol Imaging Biol; 2013 Apr; 15(2):175-85. PubMed ID: 22875335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.
    Cullinane C; Waldeck KL; Binns D; Bogatyreva E; Bradley DP; de Jong R; McArthur GA; Hicks RJ
    Nucl Med Biol; 2014 Feb; 41(2):148-54. PubMed ID: 24332383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.
    Ishii N; Harada N; Joseph EW; Ohara K; Miura T; Sakamoto H; Matsuda Y; Tomii Y; Tachibana-Kondo Y; Iikura H; Aoki T; Shimma N; Arisawa M; Sowa Y; Poulikakos PI; Rosen N; Aoki Y; Sakai T
    Cancer Res; 2013 Jul; 73(13):4050-4060. PubMed ID: 23667175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor.
    Tseng JR; Stuart D; Aardalen K; Kaplan A; Aziz N; Hughes NP; Gambhir SS
    Neoplasia; 2011 Mar; 13(3):266-75. PubMed ID: 21390189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
    Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
    PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor.
    Maynard J; Emmas SA; Blé FX; Barjat H; Lawrie E; Hancox U; Oakes D; Polanska UM; Barry ST
    EJNMMI Res; 2016 Dec; 6(1):62. PubMed ID: 27515445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
    Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
    J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors.
    Honda K; Yamamoto N; Nokihara H; Tamura Y; Asahina H; Yamada Y; Suzuki S; Yamazaki N; Ogita Y; Tamura T
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):577-84. PubMed ID: 23860959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
    Moroz MA; Kochetkov T; Cai S; Wu J; Shamis M; Nair J; de Stanchina E; Serganova I; Schwartz GK; Banerjee D; Bertino JR; Blasberg RG
    Clin Cancer Res; 2011 Mar; 17(5):1099-110. PubMed ID: 21245090
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Jiang Y; Zeng Q; Jiang Q; Peng X; Gao J; Wan H; Wang L; Gao Y; Zhou X; Lin D; Feng H; Liang S; Zhou H; Ding J; Ai J; Huang R
    Theranostics; 2022; 12(14):6395-6408. PubMed ID: 36168616
    [No Abstract]   [Full Text] [Related]  

  • 19. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
    Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
    Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts.
    Butler E; Schwettmann B; Geboers S; Hao G; Kim J; Nham K; Sun X; Laetsch TW; Xu L; Williams NS; Skapek SX
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28639. PubMed ID: 32975370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.